Clinical Trial Update: Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) [Phase 3]

View source ↗

Summary

Phase 3 open-label extension of cannabidiol (CBD) for infantile spasms completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile Spasms

Drugs mentioned

• GWP42003-P (cannabidiol) (cannabidiol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Infantile Spasms | Phase 3 | Status: COMPLETED | Results posted: 2020-07-23